OXIS International, Inc. (OTCMKTS:OXIS) has decided to appoint Cassian Yee as the new Managing Director of its scientific advisory board. The report was made public by Oxis Biotech, Inc., OXIS International’s wholly owned subsidiary.
Cassian Yee is the MD & Professor at Department of Melanoma Medical Oncology that is a division of cancer medicine at the University of Texas. Apart from this, he also works as the MD at Anderson Cancer Center and as a professor in Department of Immunology, Division of Cancer Medicine. His latest assignment makes him the Director of Solid Tumor Cell Therapy, Center for Cancer Immunology Research at the University of Texas.
Past Associations of Cassian Dr. Yee:
Previously, he worked as a member of the Department of Immunology, a clinical research division of the Fred Hutchinson Cancer Research Center and as a professor in the division of Oncology at the University of Washington. He finished medical study at the University of Manitoba in Canada. As soon as his studies got over, Dr. Yee started working as a research fellow at the Ontario Cancer Institute in Toronto. Later he got admission in Stanford University for higher studies.
Dr. Yee opted for Fred Hutchinson Cancer Research Center and the University of Washington to execute his postdoctoral research work. He has grabbed a few prominent awards including the Damon Runyon Walter Winchell Clinical Investigator Award and Cancer Research Institute Investigator Award for his work in medical science. He was recently selected as a member of the American Society for Clinical Investigation and also a Burroughs Wellcome Scientist in Translational Research.
Throughout these years, Dr. Yee’s research has focused on peripheral blood and isolation of autologous antigen-specific T cells from it. The senior management of OXIS Biotech is delighted to announce his appointment. According to Anthony J. Cataldo, CEO & Chairman, OXIS Biotech, it’s great to have Dr. Yee on board. His expertise will help OXIS transforming into a leading cancer immunotherapy company in the near future.